On the stock market since 2013, it operates in the world of health and science. It has 95 employees. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 35% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.11. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, MEDVD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MEDVD is a high-risk stock — not yet profitable, and its future rides on its product catching on.